Do analysts rate VMD or XGN?

Exagen has a consensus target price of $9.25, indicating a potential upside of 99.74%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Viemed Healthcare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viemed Healthcare 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Exagen 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78

Which has better valuation & earnings, VMD or XGN?

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viemed Healthcare $270.28M 1.48 $14.93M $0.37 28.26 Exagen $66.57M 1.68 -$19.95M -$0.89 N/A

Which has stronger valuation & earnings, XGN or AUNA?

Auna has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Auna, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 1.68 -$19.95M -$0.89 N/A Auna $4.52B 0.09 $27.39M $0.26 20.38

Is XGN or AUNA more profitable?

Auna has a net margin of 1.53% compared to Exagen's net margin of -29.49%. Auna's return on equity of 16.25% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -29.49% -94.37% -28.96% Auna 1.53% 16.25% 4.03%

Which has better valuation and earnings, XGN or SBC?

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 1.68 -$19.95M -$0.89 N/A SBC Medical Group $169.34M 1.87 $50.99M $0.39 7.94

Is XGN or SBC more profitable?

SBC Medical Group has a net margin of 24.09% compared to Exagen's net margin of -29.49%. SBC Medical Group's return on equity of 15.90% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -29.49% -94.37% -28.96% SBC Medical Group 24.09% 15.90% 11.61%

Does the media favor XGN or SBC?

In the previous week, Exagen had 1 more articles in the media than SBC Medical Group. MarketBeat recorded 2 mentions for Exagen and 1 mentions for SBC Medical Group. SBC Medical Group's average media sentiment score of 1.28 beat Exagen's score of 0.61 indicating that SBC Medical Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SBC Medical Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, LFMD or XGN?

LifeMD has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 1.23 $14.35M $0.05 99.10 Exagen $66.57M 1.68 -$19.95M -$0.89 N/A

Is LFMD or XGN more profitable?

LifeMD has a net margin of 2.37% compared to Exagen's net margin of -29.49%. Exagen's return on equity of -94.37% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% Exagen -29.49% -94.37% -28.96%

Exagen (XGN) Competitors

$4.63 +0.08 (+1.78%)

As of 01:42 PM Eastern

Compare

XGN vs. VMD, AIRS, AUNA, SBC, and LFMD

Should you buy Exagen stock or one of its competitors? MarketBeat compares Exagen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exagen include Viemed Healthcare (VMD), AirSculpt Technologies (AIRS), Auna (AUNA), SBC Medical Group (SBC), and LifeMD (LFMD). These companies are all part of the "healthcare" industry.

How does Exagen compare to Viemed Healthcare?

Viemed Healthcare (NASDAQ:VMD) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viemed Healthcare	$270.28M	1.48	$14.93M	$0.37	28.26
Exagen	$66.57M	1.68	-$19.95M	-$0.89	N/A

Viemed Healthcare has a net margin of 5.20% compared to Exagen's net margin of -29.49%. Viemed Healthcare's return on equity of 10.52% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viemed Healthcare	5.20%	10.52%	7.60%
Exagen	-29.49%	-94.37%	-28.96%

In the previous week, Exagen had 2 more articles in the media than Viemed Healthcare. MarketBeat recorded 2 mentions for Exagen and 0 mentions for Viemed Healthcare. Viemed Healthcare's average media sentiment score of 1.89 beat Exagen's score of 0.61 indicating that Viemed Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Viemed Healthcare	Very Positive
Exagen	Positive

74.2% of Viemed Healthcare shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 20.0% of Viemed Healthcare shares are held by company insiders. Comparatively, 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Viemed Healthcare has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Exagen has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market.

Exagen has a consensus target price of $9.25, indicating a potential upside of 99.74%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viemed Healthcare	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Viemed Healthcare beats Exagen on 9 of the 16 factors compared between the two stocks.

How does Exagen compare to AirSculpt Technologies?

Exagen (NASDAQ:XGN) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

AirSculpt Technologies has a net margin of -7.39% compared to Exagen's net margin of -29.49%. AirSculpt Technologies' return on equity of -4.98% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
AirSculpt Technologies	-7.39%	-4.98%	-2.36%

Exagen presently has a consensus target price of $9.25, suggesting a potential upside of 99.74%. AirSculpt Technologies has a consensus target price of $4.50, suggesting a potential downside of 11.66%. Given Exagen's stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than AirSculpt Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Exagen has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, AirSculpt Technologies has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

75.3% of Exagen shares are owned by institutional investors. Comparatively, 91.5% of AirSculpt Technologies shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Comparatively, 44.6% of AirSculpt Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Exagen had 2 more articles in the media than AirSculpt Technologies. MarketBeat recorded 2 mentions for Exagen and 0 mentions for AirSculpt Technologies. AirSculpt Technologies' average media sentiment score of 1.89 beat Exagen's score of 0.61 indicating that AirSculpt Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Exagen	Positive
AirSculpt Technologies	Very Positive

AirSculpt Technologies has higher revenue and earnings than Exagen. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.68	-$19.95M	-$0.89	N/A
AirSculpt Technologies	$151.82M	2.37	-$11.67M	-$0.17	N/A

Summary

AirSculpt Technologies beats Exagen on 11 of the 16 factors compared between the two stocks.

How does Exagen compare to Auna?

Exagen (NASDAQ:XGN) and Auna (NYSE:AUNA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Exagen has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, Auna has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Auna has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Auna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.68	-$19.95M	-$0.89	N/A
Auna	$4.52B	0.09	$27.39M	$0.26	20.38

75.3% of Exagen shares are owned by institutional investors. 10.4% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Exagen had 2 more articles in the media than Auna. MarketBeat recorded 2 mentions for Exagen and 0 mentions for Auna. Exagen's average media sentiment score of 0.61 beat Auna's score of 0.00 indicating that Exagen is being referred to more favorably in the media.

Company	Overall Sentiment
Exagen	Positive
Auna	Neutral

Auna has a net margin of 1.53% compared to Exagen's net margin of -29.49%. Auna's return on equity of 16.25% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
Auna	1.53%	16.25%	4.03%

Exagen presently has a consensus price target of $9.25, suggesting a potential upside of 99.74%. Auna has a consensus price target of $6.97, suggesting a potential upside of 31.45%. Given Exagen's stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than Auna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Auna	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

Exagen beats Auna on 9 of the 17 factors compared between the two stocks.

How does Exagen compare to SBC Medical Group?

Exagen (NASDAQ:XGN) and SBC Medical Group (NASDAQ:SBC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.68	-$19.95M	-$0.89	N/A
SBC Medical Group	$169.34M	1.87	$50.99M	$0.39	7.94

Exagen has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

In the previous week, Exagen had 1 more articles in the media than SBC Medical Group. MarketBeat recorded 2 mentions for Exagen and 1 mentions for SBC Medical Group. SBC Medical Group's average media sentiment score of 1.28 beat Exagen's score of 0.61 indicating that SBC Medical Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SBC Medical Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.3% of Exagen shares are owned by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are owned by institutional investors. 10.4% of Exagen shares are owned by company insiders. Comparatively, 81.7% of SBC Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

SBC Medical Group has a net margin of 24.09% compared to Exagen's net margin of -29.49%. SBC Medical Group's return on equity of 15.90% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
SBC Medical Group	24.09%	15.90%	11.61%

Exagen currently has a consensus price target of $9.25, indicating a potential upside of 99.74%. SBC Medical Group has a consensus price target of $8.50, indicating a potential upside of 174.64%. Given SBC Medical Group's higher possible upside, analysts clearly believe SBC Medical Group is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

SBC Medical Group beats Exagen on 11 of the 16 factors compared between the two stocks.

How does Exagen compare to LifeMD?

LifeMD (NASDAQ:LFMD) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

LifeMD has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market. Comparatively, Exagen has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

LifeMD currently has a consensus price target of $9.14, indicating a potential upside of 84.52%. Exagen has a consensus price target of $9.25, indicating a potential upside of 99.74%. Given Exagen's stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

35.5% of LifeMD shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 17.2% of LifeMD shares are held by company insiders. Comparatively, 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Exagen had 2 more articles in the media than LifeMD. MarketBeat recorded 2 mentions for Exagen and 0 mentions for LifeMD. LifeMD's average media sentiment score of 1.87 beat Exagen's score of 0.61 indicating that LifeMD is being referred to more favorably in the media.

Company	Overall Sentiment
LifeMD	Very Positive
Exagen	Positive

LifeMD has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	1.23	$14.35M	$0.05	99.10
Exagen	$66.57M	1.68	-$19.95M	-$0.89	N/A

LifeMD has a net margin of 2.37% compared to Exagen's net margin of -29.49%. Exagen's return on equity of -94.37% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Exagen	-29.49%	-94.37%	-28.96%

Summary

LifeMD beats Exagen on 8 of the 15 factors compared between the two stocks.

Get Exagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XGN vs. The Competition

Export

Metric	Exagen	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$111.89M	$8.22B	$6.49B	$12.22B
Dividend Yield	N/A	2.50%	2.67%	5.65%
P/E Ratio	-5.20	15.55	24.69	24.42
Price / Sales	1.68	6.80	495.51	91.25
Price / Cash	N/A	17.11	44.13	56.69
Price / Book	6.01	3.29	10.71	6.73
Net Income	-$19.95M	$224.06M	$3.57B	$337.78M
7 Day Performance	10.53%	-0.75%	2.56%	3.08%
1 Month Performance	27.23%	4.16%	3.03%	4.49%
1 Year Performance	-40.09%	3.84%	28.90%	31.54%

Exagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XGN Exagen	3.1288 of 5 stars	$4.63 +1.8%	$9.25 +99.7%	-38.8%	$111.89M	$66.57M	N/A	220
VMD Viemed Healthcare	2.4421 of 5 stars	$9.92 flat	N/A	+52.9%	$380.30M	$270.28M	26.81	1,382	Positive News
AIRS AirSculpt Technologies	1.5463 of 5 stars	$5.28 +5.0%	$4.50 -14.8%	-0.6%	$354.85M	$151.82M	N/A	240
AUNA Auna	4.8012 of 5 stars	$4.80 +6.1%	$6.97 +45.3%	-17.1%	$334.54M	$1.23B	18.44	15,254
SBC SBC Medical Group	3.7509 of 5 stars	$2.99 +1.0%	$8.50 +184.3%	-32.7%	$303.63M	$173.61M	7.67	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XGN) was last updated on 6/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exagen (XGN) Competitors

XGN vs. VMD, AIRS, AUNA, SBC, and LFMD

How does Exagen compare to Viemed Healthcare?

Summary

How does Exagen compare to AirSculpt Technologies?

Summary

How does Exagen compare to Auna?

Summary

How does Exagen compare to SBC Medical Group?

Summary

How does Exagen compare to LifeMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exagen (XGN) Competitors

XGN vs. VMD, AIRS, AUNA, SBC, and LFMD

How does Exagen compare to Viemed Healthcare?

Which has better valuation & earnings, VMD or XGN?

Is VMD or XGN more profitable?

Does the media favor VMD or XGN?

Do institutionals & insiders believe in VMD or XGN?

Which has more volatility and risk, VMD or XGN?

Do analysts rate VMD or XGN?

Summary

How does Exagen compare to AirSculpt Technologies?

Is XGN or AIRS more profitable?

Do analysts rate XGN or AIRS?

Which has more risk and volatility, XGN or AIRS?

Do insiders and institutionals have more ownership in XGN or AIRS?

Does the media prefer XGN or AIRS?

Which has better earnings & valuation, XGN or AIRS?

Summary

How does Exagen compare to Auna?

Which has more risk & volatility, XGN or AUNA?

Which has stronger valuation & earnings, XGN or AUNA?

Do institutionals & insiders hold more shares of XGN or AUNA?

Does the media refer more to XGN or AUNA?

Is XGN or AUNA more profitable?

Do analysts rate XGN or AUNA?

Summary

How does Exagen compare to SBC Medical Group?

Which has better valuation and earnings, XGN or SBC?

Which has more risk and volatility, XGN or SBC?

Does the media favor XGN or SBC?

Do institutionals & insiders have more ownership in XGN or SBC?

Is XGN or SBC more profitable?

Do analysts prefer XGN or SBC?

Summary

How does Exagen compare to LifeMD?

Which has more risk & volatility, LFMD or XGN?

Do analysts prefer LFMD or XGN?

Do institutionals and insiders believe in LFMD or XGN?

Does the media prefer LFMD or XGN?

Which has stronger earnings & valuation, LFMD or XGN?

Is LFMD or XGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools